Dr.ย Danielย Tan
B.Sc. (Hons), MBBS (London), MRCP (UK), PhD
Senior Consultant Medical Oncologist
corporate_fareNational Cancer Centre Singapore
Daniel Tan
B.Sc. (Hons), MBBS (London), MRCP (UK), PhD
Dr. Daniel Shao-Weng Tan is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore (NCCS) and Professor in the SingHealth Duke-NUS Oncology Academic Clinical Programme. He specialises in thoracic oncology, head and neck oncology, precision oncology, and early-phase cancer drug development.
Dr. Tan leads the Division of Clinical Trials and Epidemiological Sciences at NCCS and directs its Experimental Cancer Therapeutics Unit โ one of the largest Phase I oncology trial units in Asia, running approximately 30โ40 trials concurrently. His research focuses on the determinants of response and resistance to targeted therapy and immunotherapy, drug-resistance mechanisms, novel anti-cancer agents, and blood-based biomarkers for early cancer detection. He is also a Senior Clinician-Scientist at the Genome Institute of Singapore and chairs the Asian Thoracic Oncology Research Group. In 2025, he was awarded a S$25 million NMRC Large Collaborative Grant for the CLARION programme, a major Singapore-led initiative targeting early detection, personalised treatment, and drug-resistance research in Asian lung cancer patients. He has published more than 100 peer-reviewed articles in journals including The New England Journal of Medicine, The Lancet, Nature, Nature Genetics, and Journal of Clinical Oncology.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Daniel Tan at National Cancer Centre Singapore.
Why Consider Dr. Daniel Tan?
Dr. Tan is one of Asia's foremost thoracic oncology clinician-scientists, combining high-volume clinical practice with leadership of a major Phase I clinical-trials unit and an internationally recognised research programme.
Areas of Specialisation
Thoracic oncology, precision oncology, and early-phase cancer drug development
Dr. Tan's clinical and research work spans lung cancer, head and neck cancers, and precision oncology, with a particular focus on molecular profiling, targeted therapy, immunotherapy, and early-phase clinical trials.
Thoracic Oncology
Comprehensive medical oncology for lung and thoracic cancers, including molecular profiling and biomarker-driven systemic treatment.
- arrow_rightAdvanced non-small cell lung cancer (NSCLC) treatment planning
- arrow_rightEGFR, ALK, ROS1, and other driver mutation-guided targeted therapy
- arrow_rightPD-L1 and biomarker assessment for immunotherapy eligibility
- arrow_rightDisease monitoring and treatment-resistance management
- arrow_rightOral and IV targeted agents based on molecular profiling results
- arrow_rightPD-1 and PD-L1 checkpoint inhibitor regimens for eligible patients
- arrow_rightCombination immunotherapy and chemotherapy protocols
- arrow_rightBiomarker-driven treatment selection and resistance profiling
Head & Neck Oncology
Medical oncology management of head and neck cancers including nasopharyngeal carcinoma, laryngeal cancer, and other head and neck tumours.
- arrow_rightNasopharyngeal carcinoma (NPC) systemic treatment
- arrow_rightLaryngeal and oral cavity cancer medical oncology
- arrow_rightSalivary gland and other head and neck tumour management
- arrow_rightMultidisciplinary care coordination with surgical and radiation oncology
Precision Oncology & Cancer Drug Development
Early-phase clinical-trial leadership and translational research bridging laboratory science with new cancer treatment strategies.
- arrow_rightPhase I biomarker-driven trials including first-in-human studies
- arrow_rightNovel anti-cancer agent evaluation
- arrow_rightLiquid biopsy and ctDNA-based monitoring in trial settings
- arrow_rightDrug-resistance mechanism research and clinical translation
Procedures & Clinical Services
Medical oncology, precision diagnostics, and early-phase trial access
Dr. Tan provides comprehensive medical oncology services for thoracic and head and neck cancers, with a clinical emphasis on molecular profiling, targeted therapy, immunotherapy, and access to early-phase clinical trials at NCCS.
Medical Oncology โ Lung & Thoracic Cancers
Medical OncologyFull-spectrum medical oncology for NSCLC, SCLC, and other thoracic malignancies, from first-line systemic treatment to later-line and post-progression management.
Targeted Therapy
Targeted TherapyMolecular profiling-guided targeted treatment using approved and investigational agents, based on driver mutation status.
Molecular Diagnostics & Staging
DiagnosisComprehensive biomarker testing and molecular staging to guide precision oncology treatment decisions.
Second Opinion Consultations
Second OpinionExpert independent oncology review for patients with lung cancer, head and neck cancers, or other thoracic malignancies seeking a specialist opinion.
Research & Publications
International publications in thoracic oncology, precision oncology, and cancer drug development
Dr. Tan is an internationally recognised clinician-scientist with more than 100 peer-reviewed publications in leading journals. His research spans lung cancer genomics, drug-resistance mechanisms, targeted therapy and immunotherapy biomarkers, blood-based early detection, and early-phase clinical trial development.
Dr. Tan's Phase I unit at NCCS runs biomarker-driven trials, including first-in-human studies. CancerFax can assist in assessing eligibility for open trials where applicable.
Education & Training
Dr. Tan completed his undergraduate and postgraduate medical training in the United Kingdom, including a fellowship at the Royal Marsden Hospital, and holds a PhD in Cancer Biology from the National University of Singapore.
Clinical Experience
Dr. Tan holds multiple concurrent senior roles at National Cancer Centre Singapore, Duke-NUS Medical School, and the Genome Institute of Singapore, spanning clinical oncology, academic medicine, clinical-trial leadership, and translational research.
Languages & International
Dr. Tan conducts consultations in English.
CancerFax can coordinate certified medical interpreters for patients who require consultations in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Daniel Tan
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Daniel Tan's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Daniel Tan's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Daniel Tan before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Daniel Tan's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Daniel Tan's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Daniel Tan's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Daniel Tan
Dr. Daniel Tan specialises in thoracic oncology and head and neck oncology. NCCS lists lung cancer, thoracic cancers, head and neck cancer, nasopharyngeal carcinoma, and laryngeal cancer among the conditions he treats. His clinical work is particularly focused on cases that may benefit from molecular profiling, targeted therapy, immunotherapy, or early-phase clinical-trial access.
Dr. Tan is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore (NCCS), which serves as Singapore's national and regional tertiary cancer centre. He is also a Professor in the SingHealth Duke-NUS Oncology Academic Clinical Programme and a Senior Clinician-Scientist at the Genome Institute of Singapore.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the consultation request with NCCS, subject to availability and case acceptance. We will guide you through each step of the process.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging studies, and treatment history. The final consultation format and availability depend on NCCS scheduling. Dr. Tan's expertise in lung cancer genomics and targeted therapy makes him a relevant specialist for complex second-opinion cases.
Yes. Dr. Tan directs the Experimental Cancer Therapeutics Unit at NCCS, one of the largest Phase I oncology trial units in Asia, running approximately 30โ40 trials simultaneously including first-in-human and biomarker-driven studies. He is also Principal Investigator of the CLARION programme, a major Singapore-led lung cancer research initiative. CancerFax can assist in reviewing whether open trials may be relevant to a patient's case.
Dr. Tan's research focuses on the determinants of response and resistance to targeted therapy and immunotherapy, drug-resistance mechanisms in cancer, novel anti-cancer agents, blood-based biomarkers for early cancer detection, and precision oncology for Asian lung cancer patients. He has published more than 100 peer-reviewed articles in journals including The New England Journal of Medicine, The Lancet, Nature, and Journal of Clinical Oncology.
Connect with Daniel Tan Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.